Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Brand Name | Status | Last Update |
---|---|---|
azilect | New Drug Application | 2021-04-02 |
rasagiline | ANDA | 2024-12-09 |
rasagiline mesylate | ANDA | 2023-10-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
parkinson disease | EFO_0002508 | D010300 | G20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | 7 | 8 | 4 | 20 |
Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | — | 1 |
Sleep wake disorders | D012893 | — | G47 | — | — | — | 1 | — | 1 |
Dyssomnias | D020920 | — | — | — | — | — | 1 | — | 1 |
Parasomnias | D020447 | — | G47.5 | — | — | — | 1 | — | 1 |
Depression | D003863 | — | F33.9 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | 1 | — | — | 1 |
Paralysis | D010243 | — | — | — | — | 1 | — | — | 1 |
Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | 1 | — | — | 1 |
Psychomotor agitation | D011595 | — | — | — | 1 | 1 | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Shy-drager syndrome | D012791 | EFO_1001050 | — | — | 1 | — | — | — | 1 |
Multiple system atrophy | D019578 | — | — | — | 1 | — | — | — | 1 |
Atrophy | D001284 | — | — | — | 1 | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malignant carcinoid syndrome | D008303 | — | E34.0 | — | — | — | — | 1 | 1 |
Serotonin syndrome | D020230 | EFO_1001842 | G90.81 | — | — | — | — | 1 | 1 |
Drug common name | Rasagiline |
INN | rasagiline |
Description | Rasagiline is an indane that consists of 1-aminoindane bearing an N-propargyl substituent. A selective, irreversible monoamine oxidase-B inhibitor. It has a role as an EC 1.4.3.4 (monoamine oxidase) inhibitor and a neuroprotective agent. It is a secondary amine, a member of indanes and a terminal acetylenic compound. |
Classification | Small molecule |
Drug class | Monoamine oxidase (MAO) inhibitors, type B |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C#CCN[C@@H]1CCc2ccccc21 |
PDB | — |
CAS-ID | 136236-51-6 |
RxCUI | — |
ChEMBL ID | CHEMBL887 |
ChEBI ID | 63620 |
PubChem CID | 3052776 |
DrugBank | DB01367 |
UNII ID | 003N66TS6T (ChemIDplus, GSRS) |